The latest news from academia, regulators
research labs and other things of interest
Posted: Jul 06, 2011
Fluidigm and Life Technologies Cross-License a Broad Set of Intellectual Properties
(Nanowerk News) Fluidigm Corporation today announced that it has entered into a set of cross-licensing and sub-licensing agreements on a range of intellectual properties with Life Technologies.
Under the terms of the agreements, Fluidigm will gain broad access to patent families covering PCR related technologies of Life Technologies. In addition, Life Technologies will gain broad access to a number of Fluidigm patent families related to imaging readers and other technologies.
Recent legal actions that had been filed by both parties have been withdrawn.
"This is a very positive outcome for both companies. It provides each company with the freedom to compete in the marketplace instead of the courtroom," said Gajus Worthington, Fluidigm President and Chief Executive Officer. "We are pleased to have broad access to the PCR patent portfolio of Life Technologies. This ensures that our customers have access to a broad array of assays on our advanced systems, such as our BioMarkô HD. We are also pleased to have the first recognition of the value of our non-core IP (intellectual property), which builds significant value for others outside of our core platform."
Fluidigm develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or chips, and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including nine different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies. For more information, please visit www.fluidigm.com.